The most common treatments come with significant cardiovascular risk, but study investigators suggest newer options might offer a more favorable risk profile.
Nivolumab instead of brentuximab added onto chemotherapy is suggested as the new standard of care, based on results from the largest Hodgkin lymphoma study in National Clinical Trials Network history.